Last reviewed · How we verify
Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Infusion of Donor Hematopoietic Stem Cells and Campath-1H is a Biologic drug developed by Northwestern University. It is currently in Phase 1 development.
At a glance
| Generic name | Infusion of Donor Hematopoietic Stem Cells and Campath-1H |
|---|---|
| Sponsor | Northwestern University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- ALT, SGPT (serum glutamic pyruvic transaminase)
- Febrile neutropenia
- Leukocytes (total WBC)
- Lymphopenia
- AST, SGOT(serum glutamic oxaloacetic transaminase)
- Hemoglobin
- Neutrophils/granulocytes (ANC/AGC)
- Platelets
- Diarrhea
- Infection with normal ANC or Grade 1 or 2 neutrophils::Blood
- Phosphate, serum-low (hypophosphatemia)
- Rash/desquamation
Key clinical trials
- Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia (PHASE1, PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- HLA-Identical Sibling Renal Transplant Tolerance (NA)
- Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (PHASE2)
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies (NA)
- TMLI and Alemtuzumab for Treatment of Sickle Cell Disease (PHASE1)
- Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function (PHASE1, PHASE2)
- Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infusion of Donor Hematopoietic Stem Cells and Campath-1H CI brief — competitive landscape report
- Infusion of Donor Hematopoietic Stem Cells and Campath-1H updates RSS · CI watch RSS
- Northwestern University portfolio CI
Frequently asked questions about Infusion of Donor Hematopoietic Stem Cells and Campath-1H
What is Infusion of Donor Hematopoietic Stem Cells and Campath-1H?
Infusion of Donor Hematopoietic Stem Cells and Campath-1H is a Biologic drug developed by Northwestern University.
Who makes Infusion of Donor Hematopoietic Stem Cells and Campath-1H?
Infusion of Donor Hematopoietic Stem Cells and Campath-1H is developed by Northwestern University (see full Northwestern University pipeline at /company/northwestern-university).
What development phase is Infusion of Donor Hematopoietic Stem Cells and Campath-1H in?
Infusion of Donor Hematopoietic Stem Cells and Campath-1H is in Phase 1.
What are the side effects of Infusion of Donor Hematopoietic Stem Cells and Campath-1H?
Common side effects of Infusion of Donor Hematopoietic Stem Cells and Campath-1H include ALT, SGPT (serum glutamic pyruvic transaminase), Febrile neutropenia, Leukocytes (total WBC), Lymphopenia, AST, SGOT(serum glutamic oxaloacetic transaminase), Hemoglobin.
Related
- Manufacturer: Northwestern University — full pipeline